IP Library Granted Patent US 7,718,198
Granted Patent B2
US 7,718,198 · App. 11/326,874 · Granted May 18, 2010

Treatment modalities for autoimmune diseases

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,718,198
App. No.
11/326,874
Granted
May 18, 2010
Kind
B2
Abstract

Compositions of reduced isoalpha acids, vitamins and minerals are disclosed as well as methods of using the same for the treatment of autoimmune diseases. Additional combinations including other compounds are also contemplated. Synergistic properties and methods exploiting such synergy are also disclosed.

Claims (8)

1. A method of treating an autoimmune disease comprising a step of administering to a mammal in need thereof a therapeutically effective amount of a composition comprising a compound selected from the group consisting of dihydro-isohumulone, dihydro-isocohumulone, dihydro-isoadhumulone, tetrahydro-isohumulone, tetrahydro-isocohumulone, tetrahydro-isoadhumulone, hexahydro-isohumulone, hexahydro-isocohumulone, and hexahydro-isoadhumulone, a mineral, and a vitamin.

2. The method of claim 1 , wherein the autoimmune disease is selected from the group consisting of Crohn's disease, Raynaud's Phenomenon, rheumatoid arthritis, and systemic lupus erythematosus.

3. The method of claim 1 , wherein the mineral is selected from the group consisting of calcium, selenium, zinc, copper, iron, chromium, magnesium, manganese, vanadium, molybdenum, and boron.

4. The method of claim 1 , wherein the vitamin is selected from the group consisting of Vitamin A, Vitamin B, Vitamin C, Vitamin D, Vitamin E, Vitamin K, biotin, folate, pantothenic acid, para-aminobenzoic acid, and betaine.

5. The method of claim 1 , wherein the composition comprises about 0.5 to 10,000 mg of the compound.

6. The method of claim 1 , wherein the composition comprises about 50 to 7,500 mg of the compound.

7. The method of claim 1 , wherein the composition further comprises a pharmaceutically acceptable carrier.

8. The method of claim 1 , wherein the composition is administered orally, topically, parenterally, or rectally.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Oct 25, 2021
From: BANK OF AMERICA, N.A.
To: META PROTEOMICS, LLC
Reel/Frame 057909/0199 →
SECURITY AGREEMENT Recorded Oct 15, 2009
From: META PROTEOMICS, LLC
To: BANK OF AMERICA, N.A.
Reel/Frame 023373/0684 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 25, 2008
From: TRIPP, MATTHEW L.; BLAND, JEFFREY S.; LERMAN, ROBERT; HALL, AMY; KONDA, VEERA; DESAI, ANU
To: METAPROTEOMICS, LLC
Reel/Frame 021293/0015 →